• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Ventavis (iloprost) - Analysis and Estimates from 2003 to 2017 - Product Image

Ventavis (iloprost) - Analysis and Estimates from 2003 to 2017

  • ID: 1934512
  • July 2011
  • 37 pages
  • GlobalData

Ventavis (iloprost) - Analysis and Estimates from 2003 to 2017

Summary

GlobalData’s pharmaceuticals report, “Ventavis (iloprost) - Analysis and Estimates from 2003 to 2017” provides Ventavis sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2003-2017). The report also includes information on Pulmonary Arterial Hypertension market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Ventavis including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Pulmonary Arterial Hypertension
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Mortality
2.3 Etiology
2.3.1 Scleroderma
2.3.2 Sickle Cell Disease
2.3.3 HIV/AIDS
2.3.4 Drug Abuse and Toxins
2.4 Economic Impact of PAH
2.5 GlobalData Report Guidance
3 Pulmonary Arterial Hypertension (PAH): Market Characterization
3.1 PAH Market
3.2 PAH Market Forecasts and CAGR
3.3 PAH Market : Drivers and Restraints
3.3.1 Drivers
3.3.2 Barriers
4 Classification of PAH
4.1 Classification Based on Cause and Clinical Presentation
4.1.1 Idiopathic PAH
4.1.2 Familial PAH
4.1.3 Drug Induced PAH
4.1.4 PAH Associated with Other Conditions
4.1.5 PAH Associated with Significant Venous or Capillary Involvement
4.2 Symptomatic Profile of PAH
5 Evolution of PAH Treatments
6 Medications
6.1 Prostanoids
6.1.1 Epoprostenol
6.1.2 Treprostinil
6.1.3 Iloprost
6.1.4 Beraprost
6.2 Endothelin Receptor Antagonists
6.2.1 Bosentan
6.2.2 Ambrisentan
6.2.3 Sitaxsentan
6.3 Phosphodiesterase Type 5 Inhibitors
6.3.1 Sildenafil
6.3.2 Tadalafil
6.4 Surgical Treatments
6.5 Investigational Combination Regimens
6.6 New Targets for PAH Therapy
7 Market Share by Class in PAH
8 Ventavis (iloprost)
8.1 Introduction
8.2 Mechanism of Action
8.3 Clinical Studies
8.4 Approval History of Ventavis
8.5 Factors Affecting Sales of Ventavis
8.5.1 Approval for Increased Strength Formulation
8.5.2 Less Preferred Choice of Treatment
8.5.3 Competition from Tyvaso
8.5.4 Expiry of Orphan Drug Status
8.6 Drug Evaluation
8.6.1 Drug Risk Benefit Score
8.6.2 Intensity of Competition
8.7 Sales Estimates
8.7.1 Target Patient Pool of Ventavis
8.7.2 Dosing
8.7.3 Market Penetration
8.7.4 Annual Cost of Therapy
8.7.5 Sales Projections of Ventavis
9 PAH Market: Appendix
9.1 Market Definitions
9.2 List of Abberiviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Number of Patients Approved to take the Drug
9.3.5 Net Penetration of Drug
9.3.6 Net Annual Dosing
9.3.7 Annual Cost of Therapy
9.3.8 Primary Research
9.3.9 Expert Panels
9.4 Drug Sales Estimates Model
9.5 Contact Us
9.6 Disclaimer
9.7 Sources

1.1 List of Tables
Table 1: PAH, Global, Major Marketed Drugs
Table 2: PAH, Global, Pipeline (Phase III)
Table 3: PAH Drugs Evolution
Table 4: Change from Baseline to Week-12: Hemodynamic Parameters
Table 5: Treatment Effects of Ventavis among PAH Patients
Table 6: Adverse Events in Phase III Clinical Trials of Ventavis
Table 7: Approval History of Ventavis
Table 8: Drug Risk Benefit Score of Ventavis
Table 9: Ventavis, Annual Cost of Therapy in PAH, Global, 2010
Table 10: Ventavis, PAH, Global, Sales Estimates ($m), 2003–2017
Table 11: Ventavis, PAH, The US, Sales Estimates ($m), 2005–2017
Table 12: Ventavis, PAH, The UK, Sales Estimates ($m), 2003–2017
Table 13: Ventavis, PAH, France, Sales Estimates ($m), 2003–2017
Table 14: Ventavis, PAH, Germany, Sales Estimates ($m), 2003–2017
Table 15: Ventavis, PAH, Italy, Sales Estimates ($m), 2003–2017
Table 16: Ventavis, PAH, Spain, Sales Estimates ($m), 2003–2017

1.2 List of Figures
Figure 1: PAH, Global, Market Size Forecasts ($bn), 2010–2020
Figure 2: PAH, Worldwide, Market Share by Class (%), 2010
Figure 3: Drug Model Diagram of Ventavis
Figure 4: Ventavis, PAH, Global, Sales Estimates ($m), 2003–2017
Figure 5: Ventavis, PAH, The US, Sales Estimates ($m), 2005–2017
Figure 6: Ventavis, PAH, The UK, Sales Estimates ($m), 2003–2017
Figure 7: Ventavis, PAH, France, Sales Estimates ($m), 2003–2017
Figure 8: Ventavis, PAH, Germany, Sales Estimates ($m), 2003–2017
Figure 9: Ventavis, PAH, Italy, Sales Estimates ($m), 2003–2017
Figure 10: Ventavis, PAH, Spain, Sales Estimates ($m), 2003–2017
Figure 11: Ventavis, PAH, Global, Sales Distribution by Country (%), 2011
Figure 12: Drug Model Diagram
Figure 13: Patients Approved for the Drug

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos